Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
Top Cited Papers
- 1 January 2005
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 365 (9454) , 123-129
- https://doi.org/10.1016/s0140-6736(05)17701-0
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- New Targets and Possible New Therapeutic Approaches in the Chemotherapy of Chronic Hepatitis BHepatology, 2003
- Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersJournal of Hepatology, 2003
- Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis BHepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatmentHepatology, 1999
- Long-term follow-up of patients with chronic hepatitis B treated with interferon alfaGastroenterology, 1997
- Lamivudine resistance inimmunocompetent chronic hepatitis BJournal of Hepatology, 1997
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995
- Hepatitis B Virus ImmunopathogenesisAnnual Review of Immunology, 1995